NCT06565247: Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation |
|
|
| Not yet recruiting | 3 | 60 | NA | [18F]PSMA-PET, MRI sequences optimized for prostate cancer examinations | Region Västerbotten, Umeå University, Region Skane, Lund University | Prostate Cancer | 12/26 | 12/31 | | |
| Recruiting | 3 | 750 | Europe | Enzalutamide Oral Capsule, Xtandi, Abiraterone Oral Tablet, Zytiga, Carboplatin, Cabazitaxel 60 mg Solution for Injection, Docetaxel Injectable Solution, Radium Chloride Ra-223, Xofigo, Niraparib plus Abiraterone acetate plus Prednisone, Akeega, Capivasertib plus Docetaxel, Apalutamide, Erleada, Darolutamide, Nubeqa | Karolinska Institutet, The Swedish Research Council, Kom Op Tegen Kanker, Janssen Pharmaceutica N.V., Belgium, AstraZeneca, Cancerfonden | Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 12/26 | 12/26 | | |
| Completed | N/A | 85 | Europe | SIB Dose-Escalation Radiotherapy | Umeå University | Prostatic Neoplasms, Lymphatic Metastasis | 05/23 | 05/23 | | |
Hypo-M1, NCT04612907: Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer |
|
|
| Recruiting | N/A | 420 | Europe | Moderate hypo-fractionation, Ultra-hypo-fractionation | Umeå University | Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer | 06/26 | 09/32 | | |
